Management and Board
MetrioPharm AG
Thomas Christély – Chief Executive Officer (CEO)
- Substantial collaborations and licensing agreements with major international pharma and biotech companies
- Multiple financing transactions including a reverse IPO at the Alternative Investment Market (AIM) of the London Stock Exchange
- 2019-2021 Development and sale of the German pharma start-up MYR GmbH to Gilead Sciences Inc. for €1.15 billion plus a milestone payment of a further €300 million
Thomas Christély has more than 30 years of experience in general management, finance, corporate & business development at board level - thereof more than 25 years with private and listed biotech and pharmaceutical companies in Europe and the U.S. As CEO of MetrioPharm he focuses on corporate & business development and financing.
Wolfgang Brysch, MD - Founder and Chief Scientific Officer (CSO)
- Co-founder, entrepreneur, physician
- Senior positions at Athenion, BioMedion, Antisense Pharma, Biognostik
- Scientific experience at the Max-Planck-Institute and as Chief Scientific Officer, especially in drug development
Dr. Wolfgang Brysch was chairman of the Board of Directors of MetrioPharm AG, until he moved to the position of Chief Executive Officer in 2016 and Chief Scientific Officer from 2021. Until 2014, he was managing director of BioMedion - a successful IT company, specialising in the pharmaceutical industry. Prior to this, he worked as managing director and Chief Scientific Officer at Biognostik GmbH. During that time, Dr. Brysch was also responsible for the preclinical development of various antisense cancer drugs at Antisense Pharma. Until 1992, Dr. Brysch headed a research group for molecular neurobiology and cancer research at the Max-Planck-Institute Göttingen.
Dr. med. Stephan Rietiker – Chairman of the Board
Dr. Stephan Rietiker, a trained physician qualified to practice medicine both, in Switzerland and the United States, began his career as a physician in Switzerland. He has since gone on to establish himself as an acknowledged expert and leader in healthcare and technology. His executive positions with various global pharmaceutical and medical technology companies including Roche, Boehringer Mannheim, Schering Plough, Covance, Centerpulse and LifeWatch have earned him a strong reputation as a rounded and successful manager and turnaround specialist with extensive experience in the U.S. business world. Following a turnaround of LifeWatch and a successful sale of the company to BioTelemetry Inc., Dr. Rietiker joined the Board of BioTelemetry where he vigorously supported the acquisition of BioTelemetry Inc. by Philips for USD 2.8 B in 2021. In 2022, he incorporated EpiLunar Partners AG based in Zug, Switzerland, to invest in and develop marketable breakthrough solutions in the digital health space. Dr. Rietiker was elected to the MetrioPharm AG Board of Directors for a three-year term at the Extraordinary General Meeting held on April 17, 2025.
Dr. med. Harald Fricke – Member of the Board
Dr. Harald Fricke is a habilitated physician and independent management consultant with a focus on the strategic support of small and medium-sized pharmaceutical companies in research and development. Dr. Fricke has more than 25 years of international leadership experience in pharmaceutical R&D, regulatory strategy and translational medicine. He has held senior positions at GlaxoSmithKline, Baxter Oncology, Fresenius Biotech, Apogenix and Sotio Biotech. He developed and led global clinical projects and multicultural teams in Europe, the US and Asia, overseeing large R&D budgets. As co-founder of Apogenix, Saarmetrics and the Motion Capture Group, he drives innovation in pharmacometrics (especially rare diseases, orphan diseases) and digital health - with a particular focus on AI-enabled diagnostics and data-driven development. Dr. Harald Fricke was elected to the MetrioPharm AG Board of Directors for a three-year term at the Extraordinary General Meeting held on April 17, 2025.
Jörg Gruber – Member of the Board
Jörg Gruber is Chairman of the venture capital and corporate finance boutique Clubb Capital Limited in London and has been assisting emerging biotechnology companies since the early 1990s. His past clients include BioMarin, YM BioSciences and Raptor Pharmaceuticals. Prior to his career in venture capital, he was a banker and investment banker with UBS, Goldman Sachs and Lehman Brothers. He is Chairman of Constant Therapeutics LLC and advisor to Eisbach Bio GmbH. Previously, he served on the board of FORBIUS (Formation Biologics Inc.) until the latter's acquisition by Bristol Myers in the fall of 2020. He has been advising MetrioPharm since 2009 and was confirmed as a member of the Board of Directors of MetrioPharm AG for a further three years at the 18th Annual General Meeting on June 27, 2024.
Dr. med. Martina Muttke – Member of the Board
Dr. Martina Muttke is an accomplished global healthcare leader with over 25 years of experience in the biopharmaceutical industry. She held senior leadership positions in major global companies, including Senior Vice President at Galderma, where she built and led the global Medical Affairs function. Prior to that, she was Group Vice President at Shire/Takeda, where she was responsible for medical activities in more than 50 countries and oversaw over 200 product launches. Her extensive international experience spans Europe, Latin America and global markets, with leadership roles at Bayer and other leading healthcare companies. Dr. Muttke is now a partner at Coulter Partners, where she advises and guides boards and C-suite executives on building high-performance leadership teams and shaping organizational strategies.
She holds a doctorate in medicine from the University of Cologne and completed the Advanced Management Program at Harvard Business School. She is also an ICF-certified executive coach and investor & advisor to biotech and healthcare startups. Dr. Muttke was elected to the MetrioPharm AG Board of Directors for a three-year term at the Extraordinary General Meeting held on April 17, 2025.
Christoph von Moos – Member of the Board
Christoph von Moos is Managing Director Senior Advisor at Bank Vontobel AG. He has held management and executive positions at various banks. He advises clients on all financial matters and also assists them with private equity investments. Christoph von Moos was elected to the Board of Directors of MetrioPharm AG for a further three years at the 17th Annual General Meeting on June 20th, 2023.
Dr. Jörk Zwicker – Member of the Board
Dr. Jörk Zwicker has a technical background in chemistry and biology and is a senior partner at Zwicker Schnappauf & Partner (ZSP) Patentanwälte PartG mbB. For more than 25 years, he has been advising both start-up companies and large corporations on the strategic development, defense and enforcement of their intellectual property rights, in particular patents for biological agents such as Praluent®, Dupixent®, Toujeo®, Altuvoct®, Gohibic® and Enjaymo®. In the strategic development of product-relevant intellectual property portfolios, Dr. Zwicker's focus is on life cycle management and the interaction between patent and regulatory law. Dr. Zwicker is also Chief Legal Officer of Eisbach Bio GmbH. Dr. Jörk Zwicker was elected to the MetrioPharm AG Board of Directors for a three-year term at the Extraordinary General Meeting held on April 17, 2025.